Praluent (alirocumab) Coverage Criteria
Customize your policy alerts
Sign up for all venturacountyhealthcareplan policy alerts
Know when venturacountyhealthcareplan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and benefit coverage for Praluent (alirocumab), a PCSK9 inhibitor used for hyperlipidemia. The policy designates Praluent and Repatha as not covered benefits and directs rejection at the retail pharmacy or ESI level.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.